GeneXpertMorgan Stanley

Morgan Stanley's Steve Beuchaw initiated Cepheid (NASDAQ: CPHD) at Equal-Weight with a $30.00 price target. Beuchaw was especially worried about low margin expectations and future extensive spending. "CPHD is a share gainer in a healthy molecular diagnostics market, but we see limited upside to...